PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:

Needham 23^rd Annual Virtual Healthcare Conference

• Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
• Wednesday, April 10 at 3:45 PM ET
• Virtual

Chardan 8^th Annual Genetic Medicines & Cell Therapy Manufacturing Summit

• Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
• Monday, April 29 at 2:00 PM ET
• Virtual

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following each event.

About Carisma 

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com